{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:09:20Z","timestamp":1792886960642,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"DOI":"10.7759\/cureus.48016","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:28:46Z","timestamp":1698737326000},"source":"Crossref","is-referenced-by-count":4,"title":["Recent Advances in the Treatment of Interstitial Lung Diseases"],"prefix":"10.7759","author":[{"given":"Aneesh A","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourya","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarth","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer A","year":"2012","unstructured":"Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012, 380:689-98. 10.1016\/S0140-6736(12)61079-4","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2010.0004","article-title":"Pathogenesis of interstitial lung disease in children and adults","volume":"23","author":"Glasser SW","year":"2010","unstructured":"Glasser SW, Hardie WD, Hagood JS. Pathogenesis of interstitial lung disease in children and adults. Pediatr Allergy Immunol Pulmonol. 2010, 23:9-14. 10.1089\/ped.2010.0004","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117985","article-title":"Surfactant lipidomics in healthy children and childhood interstitial lung disease","volume":"10","author":"Griese M","year":"2015","unstructured":"Griese M, Kirmeier HG, Liebisch G, Rauch D, St\u00fcckler F, Schmitz G, Zarbock R. Surfactant lipidomics in healthy children and childhood interstitial lung disease. PLoS One. 2015, 10:e0117985. 10.1371\/journal.pone.0117985","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37132009000800012","article-title":"Chronic interstitial lung diseases in children (Article in Portuguese)","volume":"35","author":"Paiva MA","year":"2009","unstructured":"Paiva MA, Amaral SM. Chronic interstitial lung diseases in children (Article in Portuguese). J Bras Pneumol. 2009, 35:792-803. 10.1590\/s1806-37132009000800012","journal-title":"J Bras Pneumol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa608","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis","volume":"60","author":"Izuka S","year":"2021","unstructured":"Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford). 2021, 60:2348-54. 10.1093\/rheumatology\/keaa608","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.1996.11.2.113","article-title":"Clinical features of interstitial lung diseases","volume":"11","author":"Lim GI","year":"1996","unstructured":"Lim GI, Lee KH, Jeong SW, et al.. Clinical features of interstitial lung diseases. Korean J Intern Med. 1996, 11:113-21. 10.3904\/kjim.1996.11.2.113","journal-title":"Korean J Intern Med"},{"key":"ref7","article-title":"Diagnosis of ILD","volume":"73","author":"Geiser T","year":"2016","unstructured":"Geiser T, Guler S. Diagnosis of ILD. Ther Umsch. 2016, 73:7-10.","journal-title":"Ther Umsch"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328363f48d","article-title":"Update on the diagnosis and classification of ILD","volume":"19","author":"Ryerson CJ","year":"2013","unstructured":"Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med. 2013, 19:453-9. 10.1097\/MCP.0b013e328363f48d","journal-title":"Curr Opin Pulm Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2022.03.004","article-title":"Current perspective of progressive-fibrosing interstitial lung disease","volume":"60","author":"Kishaba T","year":"2022","unstructured":"Kishaba T. Current perspective of progressive-fibrosing interstitial lung disease. Respir Investig. 2022, 60:503-9. 10.1016\/j.resinv.2022.03.004","journal-title":"Respir Investig"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000787","article-title":"Interstitial lung disease throughout the rheumatoid arthritis disease course","volume":"33","author":"McDermott GC","year":"2021","unstructured":"McDermott GC, Doyle TJ, Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course. Curr Opin Rheumatol. 2021, 33:284-91. 10.1097\/BOR.0000000000000787","journal-title":"Curr Opin Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin V","year":"2019","unstructured":"Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019, 20:13. 10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242860","article-title":"Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases","volume":"15","author":"Salonen J","year":"2020","unstructured":"Salonen J, V\u00e4h\u00e4nikkil\u00e4 H, Purokivi M, Kaarteenaho R. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. PLoS One. 2020, 15:e0242860. 10.1371\/journal.pone.0242860","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15393.1","article-title":"Recent advances in lung transplantation","volume":"7","author":"Meyer KC","year":"2018","unstructured":"Meyer KC. Recent advances in lung transplantation. F1000Res. 2018, 7:1684. 10.12688\/f1000research.15393.1","journal-title":"F1000Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0134CI","article-title":"Lung transplantation","volume":"184","author":"Kotloff RM","year":"2011","unstructured":"Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med. 2011, 184:159-71. 10.1164\/rccm.201101-0134CI","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000452","article-title":"Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions","volume":"24","author":"Siddiqui FM","year":"2018","unstructured":"Siddiqui FM, Diamond JM. Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr Opin Pulm Med. 2018, 24:199-204. 10.1097\/MCP.0000000000000452","journal-title":"Curr Opin Pulm Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty KR","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al.. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019, 381:1718-27. 10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin L","year":"2015","unstructured":"Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015, 45:1434-45. 10.1183\/09031936.00174914","journal-title":"Eur Respir J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618800618","article-title":"Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience","volume":"12","author":"Rivera-Ortega P","year":"2018","unstructured":"Rivera-Ortega P, Hayton C, Blaikley J, Leonard C, Chaudhuri N. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Ther Adv Respir Dis. 2018, 12:1753466618800618. 10.1177\/1753466618800618","journal-title":"Ther Adv Respir Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi L","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, et al.. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011, 365:1079-87. 10.1056\/NEJMoa1103690","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte T","year":"2015","unstructured":"Corte T, Bonella F, Crestani B, et al.. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015, 16:116. 10.1186\/s12931-015-0276-5","journal-title":"Respir Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler O","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al.. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019, 380:2518-28. 10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland KB","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, et al.. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021, 9:96-106. 10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato M","year":"2019","unstructured":"Kato M, Sasaki S, Nakamura T, et al.. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep. 2019, 9:12062. 10.1038\/s41598-019-48593-4","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon JJ","year":"2023","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, et al.. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomized, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023, 11:87-96.","journal-title":"Lancet Respir Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi H","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, et al.. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010, 35:821-9. 10.1183\/09031936.00005209","journal-title":"Eur Respir J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1586\/erc.12.160","article-title":"Treprostinil for the treatment of pulmonary arterial hypertension","volume":"11","author":"Torres F","year":"2013","unstructured":"Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013, 11:13-25. 10.1586\/erc.12.160","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman A","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, et al.. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021, 384:325-34. 10.1056\/NEJMoa2008470","journal-title":"N Engl J Med"},{"key":"ref28","article-title":"Treprostinil","author":"Zare P","year":"2023","unstructured":"Zare P, Heller D. Treprostinil. StatPearls [Internet]. StatPearls, Treasure Island (FL); 2023."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0409-0","article-title":"A comprehensive review of treprostinil pharmacokinetics via four routes of administration","volume":"55","author":"Kumar P","year":"2016","unstructured":"Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016, 55:1495-505. 10.1007\/s40262-016-0409-0","journal-title":"Clin Pharmacokinet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a posthoc analysis of the increase study","volume":"9","author":"Nathan SD","year":"2021","unstructured":"Nathan SD, Waxman A, Rajagopal S, et al.. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a posthoc analysis of the increase study. Lancet Respir Med. 2021, 9:1266-74. 10.1016\/S2213-2600(21)00165-X","journal-title":"Lancet Respir Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12063","article-title":"BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension","volume":"12","author":"Spikes LA","year":"2022","unstructured":"Spikes LA, Bajwa AA, Burger CD, et al.. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension. Pulm Circ. 2022, 12:e12063. 10.1002\/pul2.12063","journal-title":"Pulm Circ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral Treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White RJ","year":"2020","unstructured":"White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al.. Combination therapy with oral Treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020, 201:707-17. 10.1164\/rccm.201908-1640OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12198","article-title":"Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension","volume":"13","author":"Kuwana M","year":"2023","unstructured":"Kuwana M, Abe K, Kinoshita H, et al.. Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension. Pulm Circ. 2023, 13:e12198. 10.1002\/pul2.12198","journal-title":"Pulm Circ"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692182","article-title":"Neonates effects and tolerability of treprostinil in hypertension with persistent pulmonary","volume":"37","author":"Jozefkowicz M","year":"2020","unstructured":"Jozefkowicz M, Haag DF, Mazzucchelli MT, Salgado G, Fari\u00f1a D. Neonates effects and tolerability of treprostinil in hypertension with persistent pulmonary. Am J Perinatol. 2020, 37:939-46. 10.1055\/s-0039-1692182","journal-title":"Am J Perinatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4037\/ccn2011153","article-title":"Inhaled treprostinil for the treatment of pulmonary arterial hypertension","volume":"31","author":"Poms A","year":"2011","unstructured":"Poms A, Kingman M. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Crit Care Nurse. 2011, 31:e1-10. 10.4037\/ccn2011153","journal-title":"Crit Care Nurse"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184326-recent-advances-in-the-treatment-of-interstitial-lung-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:48Z","timestamp":1707509328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184326-recent-advances-in-the-treatment-of-interstitial-lung-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.48016","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}